Ash 2022 – Argenx faces Vyvgart questions
As the group looks to expand into immune thrombocytopenia, there are several reasons to be cautious.
Horizon still has a mountain to climb
But positive mid-stage Sjögren’s data raise hopes for others still plugging away at anti-CD40 assets.
